ClinicalTrials.gg
CompletedNCT01985334Updated Mar 19, 2019Results posted

Study to Evaluate the Efficacy and Safety of Glycopyrronium or Indacaterol Maleate and Glycopyrronium Bromide Fixed-dose Combination Regarding Symptoms and Health Status in Patients With Moderate COPD Switching From Treatment With Any Standard COPD Regimen

A Phase 4 interventional study of Glycopyrronium and SABA in COPD, sponsored by Novartis Pharmaceuticals. Completed at 544 sites in 23 countries. Open to participants aged 40 Years to 95 Years. Per ClinicalTrials.gov, last updated 2019-03-19.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
4,389
Allocation
Randomized
Ages
40 Years to 95 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive — 2 open to participants now, 2 under way, 1 of them phase 3. Glycopyrrolate · Pulmonary Disease, Chronic Obstructive.

Enrollment
3rd of 73
4,389 · median 152
Started
2014
with 8 others
Phase 4
11 of 73
1 open now
Registered
38th of 73
by date
Lead sponsor
19 of 73
Novartis Pharmaceuticals

Among the 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive, this one is the 3rd largest by enrollment, is one of 9 that started in 2014, is one of 11 in phase 4, and was the 38th registered.

Pulmonary Disease, Chronic Obstructive

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 857 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

2 of the 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About glycopyrrolate

Glycopyrrolate: first FDA approval 1961 (ROBINUL FORTE), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 557 Pulmonary Disease, Chronic Obstructive studies recruiting now, 306 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 89 take healthy volunteers.

This study: 40 Years to 95 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive, or all of them as a file.
02

Study summary

The main goal of this study is to evaluate the efficacy and safety of glycopyrronium bromide and indacaterol maleate and glycopyrronium bromide fixed dose combination (FDC) in patients with moderate COPD who switch from their current COPD therapy. This study aims to provide data on how non-exacerbating, but still symptomatic patients with moderate COPD switching from their current COPD treatment to glycopyrronium bromide or indacaterol maleate and glycopyrronium bromide FDC maintain or improve their symptoms. Another purpose of this study is to increase awareness and usage of validated COPD symptoms tools and dyspnea questionnaires in order to facilitate clinical assessment and improve early diagnosis of symptomatic patients.

Read the detailed description

The treatment epoch will last 12 weeks. The total duration of the study for each patient is 12 weeks (from randomization) plus 30 days of safety follow-up.

The study has three phases: screening phase (=wash-out period, if required), treatment phase and safety follow-up phase.

Eligible patients will be randomized to either receive glycopyrronium or indacaterol maleate and glycopyrronium bromide fixed dose combination or to remain in their baseline therapy, in an allocation ratio of 3:1 for each cluster (Groups A, B, C, and D), based on their COPD symptoms and baseline treatment:

Group A: Patients treated with any SABA ( Short-acting β2-adrenergic agonist) and/or SAMA (Short-acting muscarinic antagonist) as monotherapy or in free or fixed dose combination (FDC) will be assigned to glycopyrronium or will remain in their baseline therapy (3:1) Group B: Patients treated with any LABA (Long-acting β2-adrenergic agonist) or LAMA (Long-acting muscarinic antagonist) monotherapy and mMRC score =1 point will be assigned to glycopyrronium or will remain in their baseline therapy (3:1) Group C: Patients treated with any LABA and ICS (Inhaled corticosteroid) in free or FDC will be assigned to indacaterol maleate and glycopyrronium bromide fixed dose combination or will remain in their baseline therapy (3:1) Group D: Patients treated with any LABA or LAMA monotherapy and mMRC score >1 point will be assigned to indacaterol maleate and glycopyrronium bromide fixed dose combination or will remain in their baseline therapy (3:1) Due to low recruitment in Groups A and B that would lead to a significant delay of trial completion, a protocol amendment was made in order to close the recruitment of Groups A and B at the time the randomization in Groups C and D would be completed. Recruitment of the Groups C and D continued as originally planned

03

Conditions studied

  • COPD

Keywords

  • Moderate COPD, glycopyrronium bromide, indacaterol maleate and glycopyrronium bromide FDC, NVA237, QVA149
04

Who can participate

Ages eligible
40 Years to 95 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female adults aged ≥ 40 years
  • Patients with moderate according to the GOLD criteria 2013
  • Current or ex-smokers who have a smoking history of at least 10 pack years
  • Patients with airflow limitation indicated by a postbronchodilator ≥50% and \<80% of the predicted normal value and a post-bronchodilator FEV1/FVC \<0.7 at Visit 2. Post- bronchodilator refers to within 10-15 min of inhalation of 400 μg (4x100 μg) of salbutamol
  • Patients who, at Visit 1, have been for at least 3 months on a stable dose of one of the following COPD baseline treatments: *Any SABA monotherapy (such as, but not limited to, salbutamol) *Any SAMA monotherapy (such as, but not limited to, ipratropium) *Any SABA and SAMA in free or FDC (such as, but not limited to, salbutamol/ipratropium) *Any LABA monotherapy (such as, but not limited to, formoterol, salmeterol, indacaterol) *Any LAMA monotherapy (such as, but not limited to, tiotropium, aclidinium) except glycopyrronium bromide (NVA237) *Any LABA and ICS in free (ICS such as, but not limited to, beclomethasone, fluticasone) or FDC (such as, but not limited to, salmeterol/fluticasone, formoterol/budesonide).
  • Patients with an mMRC score ≥1 at Visit 1.

Exclusion criteria

Exclusion Criteria:

  • Patients with conditions for treatment with, or having a history of reactions/ to any of the following inhaled drugs or to drugs of similar chemical classes or any component thereof: Anti-cholinergic agents, Long- and short-acting 2-adrenergic agonists, Sympathomimetic amines, Lactose or any of the other of the trial medication.
  • Patients with narrow-angle glaucoma or urinary retention, severe renal impairment (history of estimated below 30 ml/min/1.73 m2 within 12 months prior to visit 1), including those with end-stage renal disease requiring dialysis.
  • Patients with active/ clinical history of asthma.If the Investigator finds clear and compelling evidence that a patient was misdiagnosed with asthma in the past, then the burden of proof is on the Investigator to properly document this previous misdiagnosis. This documentation must include the rationale for this change in diagnosis including reference to the differential diagnosis that supports this decision.
  • Patients with a history of of any organ system (other than localized basal cell carcinoma of the skin), treated or untreated, within the past 5 years, regardless of whether there is evidence of local recurrence or .
  • Patients who have a post-bronchodilator decrease more than 10% compared to pre-bronchodilator FEV1 result at Visit 2 (see Appendix 5 for details).
  • A documented history of >1 exacerbation requiring treatment with systemic or antibiotics and/or hospitalization in the previous 12 months.
  • Patients who have NOT had a COPD exacerbation in the previous 12 months and develop a COPD exacerbation between screening (Visit 1) and (Visit 2) will not be eligible but will be permitted to be re-screened after a minimum of 6 weeks after the resolution of the COPD exacerbation. (Patients suffering an exacerbation between Visit 1 and Visit 2 can only be re-screened in case it is the first one in the previous 12 months. In case this COPD exacerbation has led to an alteration of the patient COPD treatment, before this patient can be re-screened 3 months of stable COPD treatment will be required as described in Inclusion Criterion 6).
  • Patients who, in the judgment of the investigator, have a laboratory abnormality or a clinically significant condition such as (but not limited to): *Unstable ischemic heart disease, left ventricular failure ( Class III \& IV), history of myocardial infarction,arrhythmia (excluding chronic stable atrial fibrillation). Patients with such events not considered clinically significant by the investigator may be considered for inclusion in the study.*Uncontrolled hypo-or hyperthyroidism, hypokalaemia or hyperadrenergic state. *Any condition which might compromise patient safety or compliance, interfere with evaluation, or preclude completion of the study
  • History of resting (Fridericia preferred, but Bazett acceptable) >450 msec (male) or >460 msec (female) within five years before Visit 1.
  • Patients who are treated with glycopyrronium bromide (NVA237) at visit 1 are not allowed to be included into the trialPatients on non-selective beta-blockers. Those patients may enter the study after non-selective beta-blocker withdrawal during a 7-day .
  • Patients receiving any other prohibited COPD-related medications specified in Table 5-2 Prohibited COPD related medications must undergo the required wash-out period prior to Visit 2.
  • Patients who are, in the opinion of the investigator known to be unreliable or non-compliant.
  • Patients with a (BMI) of more than 40 kg/m2.
  • Use of other drugs within 5 half-lives of enrollment or within 30 days, whichever is longer.
  • Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test.
  • Women of , defined as all women physiologically capable of becoming pregnant, unless they are using effective methods of during dosing of study treatment.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
4,389 participants (actual)

Study arms

  • Experimental
    A1 (any SABA and/or SAMA)

    Patients treated with any SABA and/or SAMA as monotherapy or in free or fixed dose combination will be assigned to glycopyrronium or will remain in their baseline therapy (3:1) during 90 days of treatment

    Drug: Glycopyrronium · Drug: SABA · Drug: SAMA

  • Experimental
    A2 (glycopyrronium)

    Patients treated with any SABA and/or SAMA as monotherapy or in free or FDC at enrollment and randomized to switch in treatment with glycopyrronium (50 μg o.d.)

    Drug: Glycopyrronium · Drug: SABA · Drug: LABA · Drug: SAMA

  • Experimental
    B1 (any LAMA or LABA and mMRC=1)

    Patients treated with any LABA or LAMA monotherapy and mMRC score =1 point at Visit 1 and randomized to remain in their baseline treatment with LABA or LAMA

    Drug: LABA · Drug: Indacaterol maleate and glycopyrronium bromide · Drug: LAMA · Drug: ICS

  • Experimental
    B2 (glycopyrronium and mMRC=1)

    Patients treated with any LABA or LAMA monotherapy and mMRC score =1 point at Visit 1 and randomized to switch in treatment with glycopyrronium (50 μg o.d.)

    Drug: LABA · Drug: Indacaterol maleate and glycopyrronium bromide · Drug: LAMA

  • Experimental
    C1 (any LABA and ICS)

    Patients treated with any LABA and ICS in free or FDC at enrollment and randomized to remain in their baseline treatment with LABA and ICS in free or FDC

    Drug: LABA · Drug: ICS

  • Experimental
    C2 (indacaterol/glycopyrronium)

    Patients treated with any LABA and ICS in free or FDC at enrollment and randomized to switch in treatment with indacaterol maleate and glycopyrronium bromide FDC (110/50 μg o.d.)

    Drug: LABA · Drug: ICS

  • Experimental
    D1 (any LAMA or LABA and mMRC>1)

    Patients treated with any LABA or LAMA monotherapy and mMRC score \>1 point at Visit 1 and randomized to remain their baseline in treatment with LABA or LAMA

    Drug: LAMA

  • Experimental
    D2 (indacaterol/glycopyrronium and mMRC>1)

    Patients treated with any LABA or LAMA monotherapy and mMRC score \>1 point at Visit 1 and randomized to switch in treatment with indacaterol maleate and glycopyrronium bromide FDC (110/50 μg o.d.).

    Drug: LAMA

Interventions

  • Glycopyrronium 50 µg capsule for inhalation via SDDPI once per day

    Also known as: glycopyrronium bromide

  • DrugSABA

    Short-acting β2-adrenergic agonist (SABA) as per approved by each country and as prescribed for each patient, used as background therapy

  • DrugLABA

    Long Acting Beta Agonist (LABA) as per approved by each country and as prescribed for each patient, used as background therapy

  • DrugIndacaterol maleate and glycopyrronium bromide

    Drug pages: Indacaterol maleate · Glycopyrrolate

    Indacaterol maleate and glycopyrronium bromide fixed dose combination (110/50 µg) capsule for inhalation via SDDPI, once a day

  • DrugLAMA

    Long Acting Muscarinic Antagonist (LAMA) as per approved by each country and as prescribed for each patient, used as background therapy

  • DrugSAMA

    Short-acting muscarinic antagonist (SAMA) as per approved by each country and as prescribed for each patient, used as background therapy

  • DrugICS

    Inhaled corticosteroid (ICS) as per approved by each country and as prescribed for each patient, used as background therapy

06

What researchers measure

Primary outcomes

  1. Trough FEV1 at Week 12 for Group: Glycopyrronium vs. Short-acting Bronchodilators (SABA and/or SAMA as Monotherapy or in Free or FDC)

    Trough FEV1 at visit 4 is defined as FEV1, computed as the mean of forced expiratory volume in 1 second 15min and 45 min pre dose measurements, at the end of the dosing interval

    Time frame: Week 12 (Visit 4)

  2. Trough FEV1 at Week 12 for Group: Glycopyrronium vs. Long-acting Bronchodilators (LABA or LAMA Monotherapy)

    Trough FEV1 at visit 4 is defined as FEV1, computed as the mean of forced expiratory volume in 1 second 15min and 45 min pre dose measurements, at the end of the dosing interval

    Time frame: Week 12 (Visit 4)

  3. Trough FEV1 at Week 12 for Group: Indacaterol Maleate and Glycopyrronium Bromide FDC vs. LABA and ICS in Free or FDC

    Trough FEV1 at visit 4 is defined as FEV1, computed as the mean of forced expiratory volume in 1 second 15min and 45 min pre dose measurements, at the end of the dosing interval.

    Time frame: Week 12 (Visit 4)

  4. Trough FEV1 at Week 12 for Group: Indacaterol Maleate and Glycopyrronium Bromide FDC vs. Long-acting Bronchodilators (LABA or LAMA Monotherapy)

    Trough FEV1 at visit 4 is defined as FEV1, computed as the mean of forced expiratory volume in 1 second 15min and 45 min pre dose measurements, at the end of the dosing interval.

    Time frame: Week 12 (Visit 4)

  5. Change From Baseline on Transition Dyspnea Index (TDI) for Groups: Glycopyrronium vs. Short-acting Bronchodilators (SABA and/or SAMA as Monotherapy or in Free or FDC)

    Transition Dyspnea Index (TDI) captures changes from baseline. The TDI score is based on three domains with each domain scored from -3 (major deterioration) to +3 (major improvement), to give an overall score of -9 to +9, a negative score indicating a deterioration from baseline. A TDI focal score of 1 is considered to be a clinically significant improvement from baseline.

    Time frame: Day 1 (baseline) and week 12

  6. Change From Baseline on Transition Dyspnea Index (TDI) for Groups: Glycopyrronium vs. Long-acting Bronchodilators (LABA or LAMA Monotherapy)

    Transition Dyspnea Index (TDI) captures changes from baseline. The TDI score is based on three domains with each domain scored from -3 (major deterioration) to +3 (major improvement), to give an overall score of -9 to +9, a negative score indicating a deterioration from baseline. A TDI focal score of 1 is considered to be a clinically significant improvement from baseline.

    Time frame: Day 1 (baseline) and week 12

  7. Change From Baseline on Transition Dyspnea Index (TDI) for Groups: Indacaterol Maleate and Glycopyrronium Bromide FDC vs. LABA and ICS in Free or FDC

    Transition Dyspnea Index (TDI) captures changes from baseline. The TDI score is based on three domains with each domain scored from -3 (major deterioration) to +3 (major improvement), to give an overall score of -9 to +9, a negative score indicating a deterioration from baseline. A TDI focal score of 1 is considered to be a clinically significant improvement from baseline.

    Time frame: Day 1 (baseline) and week 12

  8. Change From Baseline on Transition Dyspnea Index (TDI) for Groups: Indacaterol Maleate and Glycopyrronium Bromide FDC vs. Long-acting Bronchodilators (LABA or LAMA Monotherapy)

    Transition Dyspnea Index (TDI) captures changes from baseline. The TDI score is based on three domains with each domain scored from -3 (major deterioration) to +3 (major improvement), to give an overall score of -9 to +9, a negative score indicating a deterioration from baseline. A TDI focal score of 1 is considered to be a clinically significant improvement from baseline.

    Time frame: Day 1 (baseline) and week 12

Secondary outcomes

  1. Trough FEV1 at Week 12 for Group: Glycopyrronium vs. Short-acting Bronchodilators (SABA and/or SAMA as Monotherapy or in Free or FDC) or vs. Long-acting Bronchodilators (LABA or LAMA Monotherapy)

    Trough FEV1 at visit 4 is defined as FEV1, computed as the mean of forced expiratory volume in 1 second 15min and 45 min pre dose measurements, at the end of the dosing interval

    Time frame: 12 Weeks

  2. Change From Baseline on on Transition Dyspnea Index (TDI) for Groups: Glycopyrronium vs. Short-acting Bronchodilators (SABA and/or SAMA as Monotherapy or in Free or FDC) or Long-acting Bronchodilators (LABA or LAMA Monotherapy)

    Transition Dyspnea Index (TDI) captures changes from baseline. The TDI score is based on three domains with each domain scored from -3 (major deterioration) to +3 (major improvement), to give an overall score of -9 to +9, a negative score indicating a deterioration from baseline. A TDI focal score of 1 is considered to be a clinically significant improvement from baseline.

    Time frame: Day 1 (baseline) and week 12

  3. Trough FEV1 at Week 12 for Group: Indacaterol Maleate and Glycopyrronium Bromide FDC vs. LABA or LAMA Monotherapy or LABA and ICS in Free or FDC on Trough FEV1 at Week 12.

    Trough FEV1 at visit 4 is defined as FEV1, computed as the mean of forced expiratory volume in 1 second 15min and 45 min pre dose measurements, at the end of the dosing interval.

    Time frame: 12 Weeks

  4. Change From Baseline on Transition Dyspnea Index (TDI) for Groups: Indacaterol Maleate and Glycopyrronium Bromide FDC vs. LABA or LAMA Monotherapy or LABA and ICS in Free or FDC

    Transition Dyspnea Index (TDI) captures changes from baseline. The TDI score is based on three domains with each domain scored from -3 (major deterioration) to +3 (major improvement), to give an overall score of -9 to +9, a negative score indicating a deterioration from baseline. A TDI focal score of 1 is considered to be a clinically significant improvement from baseline.

    Time frame: Day 1 (baseline) and week 12

  5. Change From Baseline on Total Score of COPD Assessment Test (CAT) for Groups: Glycopyrronium and Indacaterol Maleate and Glycopyrronium Bromide FDC

    Total score of COPD Assessment Test (CAT) will be measured at baseline and at week 12. This questionnaire is completed by the patient. The score ranges from 0-40 where higher scores represent worse health status. CAT scores ≥ 10 are associated with significantly impaired health status.

    Time frame: Day 1 (baseline) and Week 12

  6. Change From Baseline on Total Score of Clinical COPD Questionnaire (CCQ) for Groups: Glycopyrronium and Indacaterol Maleate and Glycopyrronium Bromide FDC

    The Clinical COPD Questionnaire (CCQ) is a self-administered 10-item questionnaire developed to measure clinical control in patients with COPD. Patients will be instructed to recall their experiences during the previous week. They respond to each question using a 7-point scale from 0 = asymptomatic/no imitation to 6 = extremely symptomatic/totally limited. The questionnaire is divided into 3 domains (symptoms \[items 1, 2, 5, and 6\] functional \[items 7, 8, 9, and 10\] and mental state \[items 3 and 4\]). The overall clinical COPD control score and the scores of the domains are calculated by adding all the scores together and dividing this sum by the number of questions. Thus, the overall clinical COPD control score as well as the score on each of the three domains varies between 0 (very good control) to 6 (extremely poor control).

    Time frame: Day 1 (baseline) and Week 12

  7. Mean Number of Puffs of Rescue Medication Use for Groups: Glycopyrronium and Indacaterol Maleate and Glycopyrronium Bromide FDC

    Mean number of puffs of rescue medication use will be measured using eDiary data over 12 weeks of treatment.

    Time frame: 12 weeks

  8. Mean Change From Baseline Reported Symptoms of COPD for Groups: Glycopyrronium and Indacaterol Maleate and Glycopyrronium Bromide FDC

    Patient-reported symptoms of COPD combined will be measured using eDiary data reported over the 12 week treatment period. The mean total symptom scores and mean individual symptom scores for the patient were calculated for the whole study period. The mean change from baseline in the total scores and in the individual scores were summarized by treatment and were analyzed for the percentage of nights with no nighttime awakenings and percentage of days with no symptoms.

    Time frame: Baseline, 12 weeks

07

Results

Posted Mar 19, 2019

Participant flow

Participant flow — Overall Study
MilestoneA1 (Any SABA and/or SAMA)A2 (Glycopyrronium)B1 (Any LAMA or LABA and mMRC=1)B2 (Glycopyrronium and mMRC=1)C1 (Any LABA and ICS)C2 (Indacaterol/Glycopyrronium)D1 (Any LAMA or LABA and mMRC>1)D2 (Indacaterol/Glycopyrronium and mMRC>1)
Started1303874201262274822274820
The intention-to-treat (itt) population1223694201254269811268811
Completed1073033671033234666237699
Not completed2384532294015637121
Withdrew: Administrative problems11020113
Withdrew: Death10030012
Withdrew: Worsening of disease00010301
Withdrew: Other297174847
Withdrew: Protocol deviation631258417471542
Withdrew: Moderate / severe copd exacerbation5141240640819
Withdrew: Subject withdrawal of consent36228419020
Withdrew: Adverse event08226318315
Withdrew: Other423101622
Withdrew: Medication non-compliance04162313
Withdrew: Use of prohibited treatment14121620
Withdrew: Investigator decision03071104
Withdrew: Lost to follow-up02031403

Outcome measures

PrimaryTrough FEV1 at Week 12 for Group: Glycopyrronium vs. Short-acting Bronchodilators (SABA and/or SAMA as Monotherapy or in Free or FDC)

Trough FEV1 at visit 4 is defined as FEV1, computed as the mean of forced expiratory volume in 1 second 15min and 45 min pre dose measurements, at the end of the dosing interval

Time frame:
Week 12 (Visit 4)
Reported as:
Least squares mean · Liters
Trough FEV1 at Week 12 for Group: Glycopyrronium vs. Short-acting Bronchodilators (SABA and/or SAMA as Monotherapy or in Free or FDC)
LitersA1 (Any SABA and/or SAMA)A2 (Glycopyrronium)
Trough FEV1 at Week 12 for Group: Glycopyrronium vs. Short-acting Bronchodilators (SABA and/or SAMA as Monotherapy or in Free or FDC)1.8264 (1.7797 to 1.8732)1.8916 (1.8647 to 1.9185)
Statistical analysis
  • A1 (Any SABA and/or SAMA) vs A2 (Glycopyrronium) · linear mixed model · p = 0.0180
PrimaryTrough FEV1 at Week 12 for Group: Glycopyrronium vs. Long-acting Bronchodilators (LABA or LAMA Monotherapy)

Trough FEV1 at visit 4 is defined as FEV1, computed as the mean of forced expiratory volume in 1 second 15min and 45 min pre dose measurements, at the end of the dosing interval

Time frame:
Week 12 (Visit 4)
Reported as:
Least squares mean · Liters
Trough FEV1 at Week 12 for Group: Glycopyrronium vs. Long-acting Bronchodilators (LABA or LAMA Monotherapy)
LitersB1 (Any LAMA or LABA and mMRC=1)B2 (Glycopyrronium and mMRC=1)
Trough FEV1 at Week 12 for Group: Glycopyrronium vs. Long-acting Bronchodilators (LABA or LAMA Monotherapy)1.8004 (1.7768 to 1.8239)1.8215 (1.8078 to 1.8352)
Statistical analysis
  • B1 (Any LAMA or LABA and mMRC=1) vs B2 (Glycopyrronium and mMRC=1) · linear mixed model · p = <0.0001
PrimaryTrough FEV1 at Week 12 for Group: Indacaterol Maleate and Glycopyrronium Bromide FDC vs. LABA and ICS in Free or FDC

Trough FEV1 at visit 4 is defined as FEV1, computed as the mean of forced expiratory volume in 1 second 15min and 45 min pre dose measurements, at the end of the dosing interval.

Time frame:
Week 12 (Visit 4)
Reported as:
Least squares mean · Liters
Trough FEV1 at Week 12 for Group: Indacaterol Maleate and Glycopyrronium Bromide FDC vs. LABA and ICS in Free or FDC
LitersC1 (Any LABA and ICS)C2 (Indacaterol/Glycopyrronium)
Trough FEV1 at Week 12 for Group: Indacaterol Maleate and Glycopyrronium Bromide FDC vs. LABA and ICS in Free or FDC1.6847 (1.6542 to 1.7153)1.7558 (1.7378 to 1.7737)
Statistical analysis
  • C1 (Any LABA and ICS) vs C2 (Indacaterol/Glycopyrronium) · linear mixed model · p = <0.0001
PrimaryTrough FEV1 at Week 12 for Group: Indacaterol Maleate and Glycopyrronium Bromide FDC vs. Long-acting Bronchodilators (LABA or LAMA Monotherapy)

Trough FEV1 at visit 4 is defined as FEV1, computed as the mean of forced expiratory volume in 1 second 15min and 45 min pre dose measurements, at the end of the dosing interval.

Time frame:
Week 12 (Visit 4)
Reported as:
Least squares mean · Liters
Trough FEV1 at Week 12 for Group: Indacaterol Maleate and Glycopyrronium Bromide FDC vs. Long-acting Bronchodilators (LABA or LAMA Monotherapy)
LitersD1 (Any LAMA or LABA and mMRC>1)D2 (Indacaterol/Glycopyrronium and mMRC>1)
Trough FEV1 at Week 12 for Group: Indacaterol Maleate and Glycopyrronium Bromide FDC vs. Long-acting Bronchodilators (LABA or LAMA Monotherapy)1.6728 (1.6461 to 1.6994)1.7742 (1.7587 to 1.7896)
Statistical analysis
  • D1 (Any LAMA or LABA and mMRC>1) vs D2 (Indacaterol/Glycopyrronium and mMRC>1) · linear mixed model · p = <0.0001
PrimaryChange From Baseline on Transition Dyspnea Index (TDI) for Groups: Glycopyrronium vs. Short-acting Bronchodilators (SABA and/or SAMA as Monotherapy or in Free or FDC)

Transition Dyspnea Index (TDI) captures changes from baseline. The TDI score is based on three domains with each domain scored from -3 (major deterioration) to +3 (major improvement), to give an overall score of -9 to +9, a negative score indicating a deterioration from baseline. A TDI focal score of 1 is considered to be a clinically significant improvement from baseline.

Time frame:
Day 1 (baseline) and week 12
Reported as:
Least squares mean · Units on a scale
Change From Baseline on Transition Dyspnea Index (TDI) for Groups: Glycopyrronium vs. Short-acting Bronchodilators (SABA and/or SAMA as Monotherapy or in Free or FDC)
Units on a scaleA1 (Any SABA and/or SAMA)A2 (Glycopyrronium)
Change From Baseline on Transition Dyspnea Index (TDI) for Groups: Glycopyrronium vs. Short-acting Bronchodilators (SABA and/or SAMA as Monotherapy or in Free or FDC)0.5117 (-0.0073 to 1.0306)2.3005 (2.0015 to 2.5995)
Statistical analysis
  • A1 (Any SABA and/or SAMA) vs A2 (Glycopyrronium) · linear mixed model · p = <0.0001
PrimaryChange From Baseline on Transition Dyspnea Index (TDI) for Groups: Glycopyrronium vs. Long-acting Bronchodilators (LABA or LAMA Monotherapy)

Transition Dyspnea Index (TDI) captures changes from baseline. The TDI score is based on three domains with each domain scored from -3 (major deterioration) to +3 (major improvement), to give an overall score of -9 to +9, a negative score indicating a deterioration from baseline. A TDI focal score of 1 is considered to be a clinically significant improvement from baseline.

Time frame:
Day 1 (baseline) and week 12
Reported as:
Least squares mean · Units on a scale
Change From Baseline on Transition Dyspnea Index (TDI) for Groups: Glycopyrronium vs. Long-acting Bronchodilators (LABA or LAMA Monotherapy)
Units on a scaleB1 (Any LAMA or LABA and mMRC=1)B2 (Glycopyrronium and mMRC=1)
Change From Baseline on Transition Dyspnea Index (TDI) for Groups: Glycopyrronium vs. Long-acting Bronchodilators (LABA or LAMA Monotherapy)0.6969 (0.4169 to 0.9769)1.4351 (1.2718 to 1.5984)
Statistical analysis
  • B1 (Any LAMA or LABA and mMRC=1) vs B2 (Glycopyrronium and mMRC=1) · linear mixed model · p = <0.0001
PrimaryChange From Baseline on Transition Dyspnea Index (TDI) for Groups: Indacaterol Maleate and Glycopyrronium Bromide FDC vs. LABA and ICS in Free or FDC

Transition Dyspnea Index (TDI) captures changes from baseline. The TDI score is based on three domains with each domain scored from -3 (major deterioration) to +3 (major improvement), to give an overall score of -9 to +9, a negative score indicating a deterioration from baseline. A TDI focal score of 1 is considered to be a clinically significant improvement from baseline.

Time frame:
Day 1 (baseline) and week 12
Reported as:
Least squares mean · Units on a scale
Change From Baseline on Transition Dyspnea Index (TDI) for Groups: Indacaterol Maleate and Glycopyrronium Bromide FDC vs. LABA and ICS in Free or FDC
Units on a scaleC1 (Any LABA and ICS)C2 (Indacaterol/Glycopyrronium)
Change From Baseline on Transition Dyspnea Index (TDI) for Groups: Indacaterol Maleate and Glycopyrronium Bromide FDC vs. LABA and ICS in Free or FDC0.8508 (0.4676 to 1.2340)1.9491 (1.7207 to 2.1775)
Statistical analysis
  • C1 (Any LABA and ICS) vs C2 (Indacaterol/Glycopyrronium) · linear mixed model · p = <0.0001
PrimaryChange From Baseline on Transition Dyspnea Index (TDI) for Groups: Indacaterol Maleate and Glycopyrronium Bromide FDC vs. Long-acting Bronchodilators (LABA or LAMA Monotherapy)

Transition Dyspnea Index (TDI) captures changes from baseline. The TDI score is based on three domains with each domain scored from -3 (major deterioration) to +3 (major improvement), to give an overall score of -9 to +9, a negative score indicating a deterioration from baseline. A TDI focal score of 1 is considered to be a clinically significant improvement from baseline.

Time frame:
Day 1 (baseline) and week 12
Reported as:
Least squares mean · Units on a scale
Change From Baseline on Transition Dyspnea Index (TDI) for Groups: Indacaterol Maleate and Glycopyrronium Bromide FDC vs. Long-acting Bronchodilators (LABA or LAMA Monotherapy)
Units on a scaleD1 (Any LAMA or LABA and mMRC>1)D2 (Indacaterol/Glycopyrronium and mMRC>1)
Change From Baseline on Transition Dyspnea Index (TDI) for Groups: Indacaterol Maleate and Glycopyrronium Bromide FDC vs. Long-acting Bronchodilators (LABA or LAMA Monotherapy)0.8632 (0.5098 to 1.2166)2.1209 (1.9130 to 2.3288)
Statistical analysis
  • D1 (Any LAMA or LABA and mMRC>1) vs D2 (Indacaterol/Glycopyrronium and mMRC>1) · linear mixed model · p = <0.0001
SecondaryTrough FEV1 at Week 12 for Group: Glycopyrronium vs. Short-acting Bronchodilators (SABA and/or SAMA as Monotherapy or in Free or FDC) or vs. Long-acting Bronchodilators (LABA or LAMA Monotherapy)

Trough FEV1 at visit 4 is defined as FEV1, computed as the mean of forced expiratory volume in 1 second 15min and 45 min pre dose measurements, at the end of the dosing interval

Time frame:
12 Weeks
Reported as:
Least squares mean · Liters
Trough FEV1 at Week 12 for Group: Glycopyrronium vs. Short-acting Bronchodilators (SABA and/or SAMA as Monotherapy or in Free or FDC) or vs. Long-acting Bronchodilators (LABA or LAMA Monotherapy)
LitersA2 + B2A1 + B1
Trough FEV1 at Week 12 for Group: Glycopyrronium vs. Short-acting Bronchodilators (SABA and/or SAMA as Monotherapy or in Free or FDC) or vs. Long-acting Bronchodilators (LABA or LAMA Monotherapy)1.8373 (1.8250 to 1.8496)1.8065 (1.7853 to 1.8276)
SecondaryChange From Baseline on on Transition Dyspnea Index (TDI) for Groups: Glycopyrronium vs. Short-acting Bronchodilators (SABA and/or SAMA as Monotherapy or in Free or FDC) or Long-acting Bronchodilators (LABA or LAMA Monotherapy)

Transition Dyspnea Index (TDI) captures changes from baseline. The TDI score is based on three domains with each domain scored from -3 (major deterioration) to +3 (major improvement), to give an overall score of -9 to +9, a negative score indicating a deterioration from baseline. A TDI focal score of 1 is considered to be a clinically significant improvement from baseline.

Time frame:
Day 1 (baseline) and week 12
Reported as:
Least squares mean · Score on a scale
Change From Baseline on on Transition Dyspnea Index (TDI) for Groups: Glycopyrronium vs. Short-acting Bronchodilators (SABA and/or SAMA as Monotherapy or in Free or FDC) or Long-acting Bronchodilators (LABA or LAMA Monotherapy)
Score on a scaleA2 +B2A1 +B1
Change From Baseline on on Transition Dyspnea Index (TDI) for Groups: Glycopyrronium vs. Short-acting Bronchodilators (SABA and/or SAMA as Monotherapy or in Free or FDC) or Long-acting Bronchodilators (LABA or LAMA Monotherapy)1.6315 (1.4874 to 1.7756)0.6562 (0.4085 to 0.9039)
SecondaryTrough FEV1 at Week 12 for Group: Indacaterol Maleate and Glycopyrronium Bromide FDC vs. LABA or LAMA Monotherapy or LABA and ICS in Free or FDC on Trough FEV1 at Week 12.

Trough FEV1 at visit 4 is defined as FEV1, computed as the mean of forced expiratory volume in 1 second 15min and 45 min pre dose measurements, at the end of the dosing interval.

Time frame:
12 Weeks
Reported as:
Least squares mean · Liters
Trough FEV1 at Week 12 for Group: Indacaterol Maleate and Glycopyrronium Bromide FDC vs. LABA or LAMA Monotherapy or LABA and ICS in Free or FDC on Trough FEV1 at Week 12.
LitersC2 +D2C1 + D1
Trough FEV1 at Week 12 for Group: Indacaterol Maleate and Glycopyrronium Bromide FDC vs. LABA or LAMA Monotherapy or LABA and ICS in Free or FDC on Trough FEV1 at Week 12.1.7650 (1.7532 to 1.7768)1.6789 (1.6587 to 1.6992)
SecondaryChange From Baseline on Transition Dyspnea Index (TDI) for Groups: Indacaterol Maleate and Glycopyrronium Bromide FDC vs. LABA or LAMA Monotherapy or LABA and ICS in Free or FDC

Transition Dyspnea Index (TDI) captures changes from baseline. The TDI score is based on three domains with each domain scored from -3 (major deterioration) to +3 (major improvement), to give an overall score of -9 to +9, a negative score indicating a deterioration from baseline. A TDI focal score of 1 is considered to be a clinically significant improvement from baseline.

Time frame:
Day 1 (baseline) and week 12
Reported as:
Least squares mean · Score on a scale
Change From Baseline on Transition Dyspnea Index (TDI) for Groups: Indacaterol Maleate and Glycopyrronium Bromide FDC vs. LABA or LAMA Monotherapy or LABA and ICS in Free or FDC
Score on a scaleC2 +D2C1 + D1
Change From Baseline on Transition Dyspnea Index (TDI) for Groups: Indacaterol Maleate and Glycopyrronium Bromide FDC vs. LABA or LAMA Monotherapy or LABA and ICS in Free or FDC2.0354 (1.8811 to 2.1896)0.8588 (0.5983 to 1.1192)
SecondaryChange From Baseline on Total Score of COPD Assessment Test (CAT) for Groups: Glycopyrronium and Indacaterol Maleate and Glycopyrronium Bromide FDC

Total score of COPD Assessment Test (CAT) will be measured at baseline and at week 12. This questionnaire is completed by the patient. The score ranges from 0-40 where higher scores represent worse health status. CAT scores ≥ 10 are associated with significantly impaired health status.

Time frame:
Day 1 (baseline) and Week 12
Reported as:
Mean · Score
Change From Baseline on Total Score of COPD Assessment Test (CAT) for Groups: Glycopyrronium and Indacaterol Maleate and Glycopyrronium Bromide FDC
ScoreA1 (Any SABA and/or SAMA)A2 (Glycopyrronium)B1 (Any LAMA or LABA and mMRC=1)B2 (Glycopyrronium and mMRC=1)C1 (Any LABA and ICS)C2 (Indacaterol/Glycopyrronium)D1 (Any LAMA or LABA and mMRC>1)D2 (Indacaterol/Glycopyrronium and mMRC>1)
Change From Baseline on Total Score of COPD Assessment Test (CAT) for Groups: Glycopyrronium and Indacaterol Maleate and Glycopyrronium Bromide FDC0.1 ± 4.6-1.8 ± 5.30.1 ± 4.9-0.5 ± 4.6-0.4 ± 4.8-1.4 ± 5.4-0.9 ± 5.0-1.9 ± 5.3
SecondaryChange From Baseline on Total Score of Clinical COPD Questionnaire (CCQ) for Groups: Glycopyrronium and Indacaterol Maleate and Glycopyrronium Bromide FDC

The Clinical COPD Questionnaire (CCQ) is a self-administered 10-item questionnaire developed to measure clinical control in patients with COPD. Patients will be instructed to recall their experiences during the previous week. They respond to each question using a 7-point scale from 0 = asymptomatic/no imitation to 6 = extremely symptomatic/totally limited. The questionnaire is divided into 3 domains (symptoms \[items 1, 2, 5, and 6\] functional \[items 7, 8, 9, and 10\] and mental state \[items 3 and 4\]). The overall clinical COPD control score and the scores of the domains are calculated by adding all the scores together and dividing this sum by the number of questions. Thus, the overall clinical COPD control score as well as the score on each of the three domains varies between 0 (very good control) to 6 (extremely poor control).

Time frame:
Day 1 (baseline) and Week 12
Reported as:
Mean · Score
Change From Baseline on Total Score of Clinical COPD Questionnaire (CCQ) for Groups: Glycopyrronium and Indacaterol Maleate and Glycopyrronium Bromide FDC
ScoreA1 (Any SABA and/or SAMA)A2 (Glycopyrronium)B1 (Any LAMA or LABA and mMRC=1)B2 (Glycopyrronium and mMRC=1)C1 (Any LABA and ICS)C2 (Indacaterol/Glycopyrronium)D1 (Any LAMA or LABA and mMRC>1)D2 (Indacaterol/Glycopyrronium and mMRC>1)
Change From Baseline on Total Score of Clinical COPD Questionnaire (CCQ) for Groups: Glycopyrronium and Indacaterol Maleate and Glycopyrronium Bromide FDC-0.0 ± 0.6-0.3 ± 0.70.0 ± 0.7-0.1 ± 0.7-0.1 ± 0.7-0.2 ± 0.8-0.1 ± 0.8-0.3 ± 0.8
SecondaryMean Number of Puffs of Rescue Medication Use for Groups: Glycopyrronium and Indacaterol Maleate and Glycopyrronium Bromide FDC

Mean number of puffs of rescue medication use will be measured using eDiary data over 12 weeks of treatment.

Time frame:
12 weeks
Reported as:
Mean · Number of puffs
Mean Number of Puffs of Rescue Medication Use for Groups: Glycopyrronium and Indacaterol Maleate and Glycopyrronium Bromide FDC
Number of puffsA1 (Any SABA and/or SAMA)A2 (Glycopyrronium)B1 (Any LAMA or LABA and mMRC=1)B2 (Glycopyrronium and mMRC=1)C1 (Any LABA and ICS)C2 (Indacaterol/Glycopyrronium)D1 (Any LAMA or LABA and mMRC>1)D2 (Indacaterol/Glycopyrronium and mMRC>1)
Mean Number of Puffs of Rescue Medication Use for Groups: Glycopyrronium and Indacaterol Maleate and Glycopyrronium Bromide FDC1.8 ± 1.71.0 ± 1.30.8 ± 1.20.7 ± 1.11.6 ± 1.71.1 ± 1.41.4 ± 1.41.1 ± 1.3
SecondaryMean Change From Baseline Reported Symptoms of COPD for Groups: Glycopyrronium and Indacaterol Maleate and Glycopyrronium Bromide FDC

Patient-reported symptoms of COPD combined will be measured using eDiary data reported over the 12 week treatment period. The mean total symptom scores and mean individual symptom scores for the patient were calculated for the whole study period. The mean change from baseline in the total scores and in the individual scores were summarized by treatment and were analyzed for the percentage of nights with no nighttime awakenings and percentage of days with no symptoms.

Time frame:
Baseline, 12 weeks
Reported as:
Mean · Percentage of days
Mean Change From Baseline Reported Symptoms of COPD for Groups: Glycopyrronium and Indacaterol Maleate and Glycopyrronium Bromide FDC
Percentage of daysA1 (Any SABA and/or SAMA)A2 (Glycopyrronium)B1 (Any LAMA or LABA and mMRC=1)B2 (Glycopyrronium and mMRC=1)C1 (Any LABA and ICS)C2 (Indacaterol/Glycopyrronium)D1 (Any LAMA or LABA and mMRC>1)D2 (Indacaterol/Glycopyrronium and mMRC>1)
Mean Change From Baseline Reported Symptoms of COPD for Groups: Glycopyrronium and Indacaterol Maleate and Glycopyrronium Bromide FDC-0.04 ± 0.15-0.10 ± 0.22-0.03 ± 0.19-0.05 ± 0.20-0.05 ± 0.19-0.07 ± 0.22-0.04 ± 0.19-0.09 ± 0.21

Adverse events

Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
A1 (Any SABA and/or SAMA)—4/125 (3.2%)19/125 (15.2%)
A2 (Glycopyrronium)—9/385 (2.3%)67/385 (17.4%)
B1 (Any LAMA or@ LABA and mMRC eq 1)—11/417 (2.6%)63/417 (15.1%)
B2 (Glycopyrronium@ and mMRC eq 1)—30/1,248 (2.4%)163/1,248 (13.1%)
C1 (Any LABA and ICS)—6/269 (2.2%)29/269 (10.8%)
C2 (Indacaterol/@Glycopyrronium)—22/816 (2.7%)119/816 (14.6%)
D1 (Any LAMA or@ LABA and mMRC gt 1)—10/269 (3.7%)20/269 (7.4%)
D2 (Indacaterol/@Glycopyrronium and@ mMRC gt 1)—34/814 (4.2%)120/814 (14.7%)
Most frequent serious events
Showing 10 of 115
Most frequent serious events
EventA1 (Any SABA and/or SAMA)A2 (Glycopyrronium)B1 (Any LAMA or@ LABA and mMRC eq 1)B2 (Glycopyrronium@ and mMRC eq 1)C1 (Any LABA and ICS)C2 (Indacaterol/@Glycopyrronium)D1 (Any LAMA or@ LABA and mMRC gt 1)D2 (Indacaterol/@Glycopyrronium and@ mMRC gt 1)
PneumoniaInfections and infestations0/1251/3850/4172/12480/2691/8161/2697/814
Cardiac arrestCardiac disorders1/1250/3850/4170/12480/2690/8160/2690/814
Myocardial infarctionCardiac disorders1/1250/3850/4171/12480/2690/8161/2691/814
HydroceleCongenital, familial and genetic disorders1/1250/3850/4170/12480/2690/8160/2690/814
Lung adenocarcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/1250/3850/4171/12480/2690/8160/2690/814
Transient ischaemic attackNervous system disorders1/1250/3850/4170/12480/2690/8160/2690/814
Pulmonary haemorrhageRespiratory, thoracic and mediastinal disorders1/1250/3850/4170/12480/2690/8160/2690/814
Coronary artery diseaseCardiac disorders0/1252/3851/4170/12480/2690/8160/2690/814
Angina unstableCardiac disorders0/1250/3850/4170/12480/2690/8161/2690/814
Arteriosclerosis coronary arteryCardiac disorders0/1250/3850/4170/12481/2690/8160/2690/814
Most frequent other events
Showing 10 of 14
Most frequent other events
EventA1 (Any SABA and/or SAMA)A2 (Glycopyrronium)B1 (Any LAMA or@ LABA and mMRC eq 1)B2 (Glycopyrronium@ and mMRC eq 1)C1 (Any LABA and ICS)C2 (Indacaterol/@Glycopyrronium)D1 (Any LAMA or@ LABA and mMRC gt 1)D2 (Indacaterol/@Glycopyrronium and@ mMRC gt 1)
NasopharyngitisInfections and infestations8/12538/38524/41771/124811/26937/81610/26954/814
CoughRespiratory, thoracic and mediastinal disorders3/1255/38513/41733/12485/26944/8164/26927/814
PharyngitisInfections and infestations3/1251/3850/4177/12480/2693/8161/2695/814
DyspnoeaRespiratory, thoracic and mediastinal disorders1/1255/3856/41713/12486/2697/8162/2697/814
HeadacheNervous system disorders0/1257/3853/4179/12481/26912/8161/2698/814
RhinitisInfections and infestations0/1251/3857/41712/12482/2695/8161/26910/814
HypertensionVascular disorders1/1253/3857/4177/12482/2695/8160/2697/814
DyspepsiaGastrointestinal disorders2/1250/3851/4173/12480/2692/8160/2691/814
TracheitisInfections and infestations2/1250/3852/4172/12480/2692/8160/2692/814
Urinary tract infectionInfections and infestations2/1252/3851/4175/12480/2691/8160/2693/814

Baseline characteristics

Age, Continuous
Age, Continuous(Years)A1 (Any SABA and/or SAMA)A2 (Glycopyrronium)B1 (Any LAMA or LABA and mMRC=1)B2 (Glycopyrronium and mMRC=1)C1 (Any LABA and ICS)C2 (Indacaterol/Glycopyrronium)D1 (Any LAMA or LABA and mMRC>1)D2 (Indacaterol/Glycopyrronium and mMRC>1)Total
Mean64.2 ± 8.263.2 ± 8.364.6 ± 8.164.4 ± 8.264.4 ± 9.064.7 ± 8.765.1 ± 7.665.4 ± 8.364.6 ± 8.3
Sex: Female, Male
Sex: Female, Male(Participants)A1 (Any SABA and/or SAMA)A2 (Glycopyrronium)B1 (Any LAMA or LABA and mMRC=1)B2 (Glycopyrronium and mMRC=1)C1 (Any LABA and ICS)C2 (Indacaterol/Glycopyrronium)D1 (Any LAMA or LABA and mMRC>1)D2 (Indacaterol/Glycopyrronium and mMRC>1)Total
Female48119131376106286952761437
Male822682898861685361795442952
08

Study locations

544 sites
  • Novartis Investigative Site
    Amstetten, 3300, Austria
  • Novartis Investigative Site
    Feldkirch, 6800, Austria
  • Novartis Investigative Site
    Hallein, 5400, Austria
  • Novartis Investigative Site
    Kirchdorf an der Krems, 4560, Austria
  • Novartis Investigative Site
    Leoben, 8700, Austria
  • Novartis Investigative Site
    Linz, 4020, Austria
  • Novartis Investigative Site
    Perg, 4320, Austria
  • Novartis Investigative Site
    Salzburg, 5020, Austria
  • Novartis Investigative Site
    Wels, 4600, Austria
  • Novartis Investigative Site
    Gosselies, BEL 6041, Belgium
  • Novartis Investigative Site
    Gozee, BEL 6534, Belgium
  • Novartis Investigative Site
    Zichem, BEL 3271, Belgium
  • Novartis Investigative Site
    Antwerpen, 2060, Belgium
  • Novartis Investigative Site
    Balen, 2490, Belgium
  • Novartis Investigative Site
    Braine l'Alleud, 1420, Belgium
  • Novartis Investigative Site
    Brussels, 1070, Belgium
  • Novartis Investigative Site
    Bruxelles, 1000, Belgium
  • Novartis Investigative Site
    Bruxelles, 1200, Belgium
  • Novartis Investigative Site
    Eghezee, 5310, Belgium
  • Novartis Investigative Site
    Erpent, 5100, Belgium
  • Novartis Investigative Site
    Geraardsbergen, 9500, Belgium
  • Novartis Investigative Site
    Gilly, 6060, Belgium
  • Novartis Investigative Site
    Halen, 3545, Belgium
  • Novartis Investigative Site
    Hasselt, 3500, Belgium
  • Novartis Investigative Site
    Heusy, 4802, Belgium
  • Novartis Investigative Site
    Ieper, 8900, Belgium
  • Novartis Investigative Site
    Knokke-Heist, 8300, Belgium
  • Novartis Investigative Site
    Lebbeke, 9280, Belgium
  • Novartis Investigative Site
    Liege, 4000, Belgium
  • Novartis Investigative Site
    Maaseik, 3680, Belgium
  • Novartis Investigative Site
    Malmedy, 4960, Belgium
  • Novartis Investigative Site
    Mechelen, 2800, Belgium
  • Novartis Investigative Site
    Melsbroek, 1820, Belgium
  • Novartis Investigative Site
    Merksem, 2170, Belgium
  • Novartis Investigative Site
    Montegnée, 4420, Belgium
  • Novartis Investigative Site
    Natoye, 5360, Belgium
  • Novartis Investigative Site
    Paal-Beringen, 3583, Belgium
  • Novartis Investigative Site
    Ronse, 9600, Belgium
  • Novartis Investigative Site
    Saint-Medard, 6887, Belgium
  • Novartis Investigative Site
    Seraing, 4100, Belgium
  • Novartis Investigative Site
    Tournai, 7500, Belgium
  • Novartis Investigative Site
    Verviers, 4800, Belgium
  • Novartis Investigative Site
    Vilvoorde, 1800, Belgium
  • Novartis Investigative Site
    Zottegem, 9620, Belgium
  • Novartis Investigative Site
    Boskovice, Czech Republic 680 01, Czechia
  • Novartis Investigative Site
    Brandys Nad Labem, Czech Republic 25001, Czechia
  • Novartis Investigative Site
    Brno-Kralovo Pole, Czech Republic 61200, Czechia
  • Novartis Investigative Site
    Cvikov, Czech Republic 471 54, Czechia
  • Novartis Investigative Site
    Havlickuv Brod, Czech Republic 580 01, Czechia
  • Novartis Investigative Site
    Jirkov, Czech Republic 43111, Czechia
  • Novartis Investigative Site
    Kurim, Czech Republic 66434, Czechia
  • Novartis Investigative Site
    Liberec, Czech Republic 460 01, Czechia
  • Novartis Investigative Site
    Lovosice, Czech Republic 410 02, Czechia
  • Novartis Investigative Site
    Neratovice, Czech Republic 27711, Czechia
  • Novartis Investigative Site
    Ostrava, Czech Republic 708 68, Czechia
  • Novartis Investigative Site
    Pardubice, Czech Republic 530 09, Czechia
  • Novartis Investigative Site
    Plzen, Czech Republic 33011, Czechia
  • Novartis Investigative Site
    Plzen, Czech Republic 331 01, Czechia
  • Novartis Investigative Site
    Prague 4, Czech Republic 142 00, Czechia
  • Novartis Investigative Site
    Prague, Czech Republic 130 00, Czechia
  • Novartis Investigative Site
    Praha 10, Czech Republic 108 00, Czechia
  • Novartis Investigative Site
    Praha 4, Czech Republic 140 46, Czechia
  • Novartis Investigative Site
    Praha 6, Czech Republic 163 00, Czechia
  • Novartis Investigative Site
    Praha 9, Czech Republic 19000, Czechia
  • Novartis Investigative Site
    Praha, Czech Republic 14800, Czechia
  • Novartis Investigative Site
    Rokycany, Czech Republic 337 22, Czechia
  • Novartis Investigative Site
    Rudna, Czech Republic 25219, Czechia
  • Novartis Investigative Site
    Teplice, Czech Republic 415 01, Czechia
  • Novartis Investigative Site
    Trebic, Czech Republic 674 01, Czechia
  • Novartis Investigative Site
    Varnsdorf, Czech Republic 40747, Czechia
  • Novartis Investigative Site
    Zatec, Czech Republic 438 01, Czechia
  • Novartis Investigative Site
    Znojmo, Czech Republic 672 01, Czechia
  • Novartis Investigative Site
    Praha 8, 182 00, Czechia
  • Novartis Investigative Site
    Alleroed, 3450, Denmark
  • Novartis Investigative Site
    Greve, 2670, Denmark
  • Novartis Investigative Site
    Haslev, 4690, Denmark
  • Novartis Investigative Site
    Søborg, 2860, Denmark
  • Novartis Investigative Site
    Værløse, 3500, Denmark
  • Novartis Investigative Site
    Paide, 72714, Estonia
  • Novartis Investigative Site
    Tallinn, 10138, Estonia
  • Novartis Investigative Site
    Tallinn, 10617, Estonia
  • Novartis Investigative Site
    Tallinn, 13419, Estonia
  • Novartis Investigative Site
    Tallinn, 13619, Estonia
  • Novartis Investigative Site
    Tartu, 51014, Estonia
  • Novartis Investigative Site
    Tours Cedex 9, Indre Et Loire 37044, France
  • Novartis Investigative Site
    Briis Sous Forges, 91640, France
  • Novartis Investigative Site
    Chamalieres, 63400, France
  • Novartis Investigative Site
    Chatellerault, 86100, France
  • Novartis Investigative Site
    Forbach, 57600, France
  • Novartis Investigative Site
    L'Aigle, 61305, France
  • Novartis Investigative Site
    La Bouexiere, 35340, France
  • Novartis Investigative Site
    Marseille, 13003, France
  • Novartis Investigative Site
    Montpellier, 34080, France
  • Novartis Investigative Site
    Murs Erigne, 49610, France
  • Novartis Investigative Site
    Nice, 06000, France
  • Novartis Investigative Site
    Saint Jean de Luz, 64500, France
  • Novartis Investigative Site
    Saint Laurent Du Var, 06721, France
  • Novartis Investigative Site
    Saint Pierre, 97448, France
  • Novartis Investigative Site
    Strasbourg, 67000, France
  • Novartis Investigative Site
    Toulon, 83000, France

Showing the first 100 of 544 sites across 23 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Greulich T, Kostikas K, Gaga M, Aalamian-Mattheis M, Lossi NS, Patalano F, Nunez X, Pagano VA, Fogel R, Vogelmeier CF, Clemens A. Indacaterol/glycopyrronium reduces the risk of clinically important deterioration after direct switch from baseline therapies in patients with moderate COPD: a post hoc analysis of the CRYSTAL study. Int J Chron Obstruct Pulmon Dis. 2018 Apr 16;13:1229-1237. doi: 10.2147/COPD.S159732. eCollection 2018. PubMed 29713156 ↗
  • Vogelmeier CF, Gaga M, Aalamian-Mattheis M, Greulich T, Marin JM, Castellani W, Ninane V, Lane S, Nunez X, Patalano F, Clemens A, Kostikas K; CRYSTAL study investigators. Efficacy and safety of direct switch to indacaterol/glycopyrronium in patients with moderate COPD: the CRYSTAL open-label randomised trial. Respir Res. 2017 Jul 18;18(1):140. doi: 10.1186/s12931-017-0622-x. PubMed 28720132 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2014 to primary completion in Apr 2016, 26 months.

Results were first posted in Mar 2019, 2 years 10 months after primary completion.

Of 71 industry-sponsored phase 4 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 22. This study's 26 months is above that.

Counting every sponsor, half of 157 studies reached it within 19 months; a quarter within 12 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 4, 2013
First posted
Nov 15, 2013
StartActual
Feb 14, 2014
Primary completionActual
Apr 29, 2016
CompletionActual
Apr 29, 2016
Results first posted
Mar 19, 2019
Last update
Mar 19, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 19, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01985334
Responsible party
Sponsor
First posted
Nov 15, 2013
Start date
Feb 14, 2014
Primary completion
Apr 29, 2016
Completion
Apr 29, 2016
Results posted
Mar 19, 2019
Last update
Mar 19, 2019

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Glycopyrrolate · Indacaterol maleate

Start the discussion